Patients with prostate cancer with: -suspected metastasis who are candidates for initial definitive therapy -suspected recurrence based on elevated serum prostate-specific antigen (PSA) level (i.e., a progressive and confirmed serum PSA level > 0.2 ng/mL) -metastatic disease who might be candidates for treatment with 177Lu-labelled PSMA ligands

1 total trials

Filter these 1 trials by phase, country, sponsor and more.

Open in Search →

Showing 1–1 of 1 trials